GlassScriptPhysician profile
Christina Travisono
NPI 1356672463
$6,852.78
in general payments reported to CMS, 2019-2025
22 companies · $5,560 in 2025
The $5,560 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $333 · 2024: $960 · 2025: $5,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,193 · Education: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,193.20 |
| Education | $659.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,728.79 | 2023-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $987.76 | 2024-2025 | |
| Leo Pharma INC. | $874.96 | 2024-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $621.33 | 2024-2025 | Dupixent, Libtayo |
| Amgen INC. | $375.53 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $303.23 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $286.56 | 2025 | |
| Genzyme Corporation | $281.75 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $261.09 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.87 | 2024-2025 | Sotyktu |
| Incyte Corporation | $206.31 | 2023-2025 | Opzelura |
| Organon LLC | $166.66 | 2025 | Vtama, Hadlima |
| Lilly USA, LLC | $113.09 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Fresenius Kabi USA, LLC | $78.90 | 2025 | Idacio |
| Galderma Laboratories, L.P. | $77.58 | 2025 | Nemluvio, Aklief |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $61.58 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.01 | 2025 | Cabtreo |
| Botanix Sb INC | $43.05 | 2025 | Sofdra |
| Merck Sharp & Dohme LLC | $33.65 | 2025 | Keytruda |
| Pfizer INC. | $20.26 | 2025 | |
| Dermavant Sciences, INC. | $17.47 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.35 | 2025 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Travisono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.